Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) shares hit a new 52-week low on Monday . The company traded as low as $17.86 and last traded at $18.23, with a volume of 112863 shares trading hands. The stock had previously closed at $19.93.
Analysts Set New Price Targets
A number of research firms have recently commented on CLDX. HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Friday, February 28th. UBS Group started coverage on Celldex Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $44.00 price objective on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Morgan Stanley started coverage on shares of Celldex Therapeutics in a research report on Thursday, March 20th. They set an "overweight" rating and a $46.00 price target on the stock. Finally, The Goldman Sachs Group cut their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $54.33.
Get Our Latest Stock Report on CLDX
Celldex Therapeutics Price Performance
The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -6.14 and a beta of 1.59. The business's 50-day moving average price is $21.35 and its 200 day moving average price is $25.75.
Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. The firm had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. As a group, sell-side analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the business. Wellington Management Group LLP increased its holdings in Celldex Therapeutics by 14.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company's stock worth $314,190,000 after purchasing an additional 1,167,659 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Celldex Therapeutics by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company's stock worth $98,098,000 after buying an additional 12,213 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Celldex Therapeutics by 23.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock worth $89,890,000 after buying an additional 676,771 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in Celldex Therapeutics by 50.8% in the fourth quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock valued at $63,579,000 after acquiring an additional 847,264 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Celldex Therapeutics by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company's stock valued at $52,372,000 after acquiring an additional 6,557 shares during the last quarter.
About Celldex Therapeutics
(
Get Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
See Also
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
